MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Articles
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Researchers believe 'magic' mushrooms have the potential to curb obesity
Researchers have started to explore the potential for psilocybin, the psychedelic drug found in "magic" mushrooms, to treat obesity.
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Novamind Expands Psychedelic Medicine Access in Utah
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
Mexico Publishes Medical Cannabis Regulations
This Tuesday, Mexico quietly passed and published rules that would regulate medical cannabis, setting up Mexico for a nation-wide cannabis industry, and taking another step towards overall cannabis reform in a nation that has been under the spotlight for a long time when it comes to cannabis regulation.
Top Texas Lawmakers Say Medical Marijuana Expansion Is On The Table For 2021
As Texas lawmakers returned to work for a new session this week, leaders of both chambers of the state’s legislature said they expect to see action on marijuana bills this year, particularly when it comes to expanding the state’s limited medical cannabis program.
This is Why the Psilocybin Story is Quickly Gaining Momentum
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases, ‘Regardless Of The Amount’
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.
Washtenaw County Prosecutor: No more charges in cannabis, psychedelic plant cases
ANN ARBOR – Washtenaw County Prosecutor Eli Savit announced Tuesday that his office will no longer bring charges in cases related to marijuana or entheogenic plant use, possession or small-scale distribution.
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?